7月23日，Medpace Holdings盘后上涨19.2%，报629.5美元/股，成交额3012.56万美元。
消息面上，公司公布第二季度财报，各项核心指标全面超越市场预期。Q2每股收益4.25美元，超出分析师预期的3.97-3.98美元约7%，同比大增37.1%；营收7.073亿美元，超出预期的6.876亿美元，同比增长17.2%。新业务订单达7.957亿美元，同比增长28.2%，净订单出货比（Book-to-Bill）为1.13倍，显示在手订单持续扩张。此外，公司上调全年指引，预计全年营收28.1亿至28.9亿美元，高于市场预期的27.7亿美元；全年EPS预计17.25至17.95美元，亦超出分析师预期的16.97美元。业绩增长与指引上调双重利好推动股价盘后大幅走高。
Medpace是全球领先的临床合同研究组织（CRO），专注于为生物技术、制药和医疗器械行业提供I至IV期全流程临床开发服务，在肿瘤学、代谢疾病等领域具有突出优势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.